Agios Pharmaceuticals
AGIO
160 hedge funds and large institutions have $1.7B invested in Agios Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 47 increasing their positions, 58 reducing their positions, and 21 closing their positions.
10% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 21
0.6% more ownership
Funds ownership: 109.02% → 109.62% (+0.6%)
0% more funds holding
Funds holding: 160 → 160 (0)
13% less capital invested
Capital invested by funds: $1.95B → $1.7B (-$245M)
13% less call options, than puts
Call options by funds: $8.77M | Put options by funds: $10.1M
19% less repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 58
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
+$10.5M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$9.2M |
| 3 |
Norges Bank
Oslo,
Norway
|
+$8.87M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$8.71M |
| 5 |
Axa
Paris,
France
|
+$6.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$18.8M |
| 2 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$6.72M |
| 3 |
BlackRock
New York
|
-$6.31M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$5.41M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$4.26M |
AGIO Hedge Fund Activity: Q1 2022 in Review
160 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q1 2022, worth a combined $1.7B — down 13% from $1.95B a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new AGIO positions and 21 closed out — a net gain of 2 holders — while 47 added to existing stakes and 58 trimmed.
The largest buyer was First Trust Advisors, adding an estimated $10.5M. The largest seller was Fidelity Investments, cutting an estimated $18.8M.
- 160 institutional investors held Agios Pharmaceuticals (AGIO) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $1.7B of Agios Pharmaceuticals stock for Q1 2022, down 13% quarter-over-quarter.
- 23 funds opened new Agios Pharmaceuticals positions in Q1 2022 and 21 closed out, a net change of +2 holders.
- The largest Agios Pharmaceuticals buyer in Q1 2022 was First Trust Advisors, an estimated $10.5M added.
- The largest Agios Pharmaceuticals seller in Q1 2022 was Fidelity Investments, an estimated $18.8M sold.
Based on aggregated 13F filings for Q1 2022.